GHRP-2: The Ghrelin Receptor Agonist for Growth Hormone Research

GHRP-2 (Growth Hormone Releasing Peptide-2, also known by its pharmaceutical name pralmorelin) represents a significant development in growth hormone secretagogue research—a synthetic hexapeptide that mimics the action of ghrelin, the endogenous gut hormone that regulates growth hormone secretion and appetite. Developed through structure-activity optimization of earlier growth hormone releasing peptides, GHRP-2 acts as a potent agonist at the growth hormone secretagogue receptor (GHS-R1a), triggering robust GH release from the anterior pituitary. The peptide has been approved in Japan as a diagnostic agent for growth hormone deficiency and continues to be studied for its effects on endocrine function, body composition, and metabolic regulation.

The discovery of GHRP-2 emerged from decades of research into the mechanisms controlling growth hormone secretion. While growth hormone releasing hormone (GHRH) was known to stimulate GH release through its specific receptor, a second pathway involving distinct receptors was suggested by the activity of synthetic peptides. The eventual identification of the ghrelin receptor (GHS-R1a) and its endogenous ligand ghrelin provided the molecular basis for understanding how GHRP-2 and related compounds function.

Molecular Structure and Design

GHRP-2 is a synthetic hexapeptide with the amino acid sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2. The structure incorporates several non-natural amino acids that enhance metabolic stability and receptor affinity:

D-Alanine (position 1): The D-configuration at the N-terminus protects against aminopeptidase degradation, extending half-life compared to all-L peptides.

D-2-Naphthylalanine (D-β-Nal, position 2): This bulky aromatic amino acid replaces the D-tryptophan found in GHRP-6, conferring enhanced binding affinity for GHS-R1a. The naphthyl side chain improves hydrophobic contacts within the receptor binding pocket, increasing potency.

L-Alanine (position 3): Provides structural spacing and flexibility.

L-Tryptophan (position 4): The indole side chain contributes to receptor binding and may interact with specific aromatic residues in GHS-R1a.

D-Phenylalanine (position 5): The D-configuration provides protease resistance while the phenyl ring contributes to binding affinity.

L-Lysinamide (position 6): The C-terminal amide and basic lysine side chain are important for biological activity and receptor interaction.

The molecular formula is C45H55N9O6, with a molecular weight of approximately 818 daltons. The strategic use of D-amino acids and unnatural aromatic residues transforms a simple peptide into a metabolically stable, high-affinity receptor ligand.

Mechanism of Action: GHS-R1a Activation

GHRP-2 exerts its effects primarily through activation of the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein-coupled receptor expressed in the hypothalamus and anterior pituitary. This is the same receptor that responds to endogenous ghrelin, often called the “hunger hormone.”

The signaling cascade proceeds as follows:

Receptor Binding: GHRP-2 binds to GHS-R1a with high affinity, stabilizing the receptor’s active conformation. The binding site overlaps with but is distinct from the GHRH receptor, explaining why GHRP-2 can stimulate GH release even when GHRH signaling is blocked.

G-protein Activation: Receptor activation triggers Gq/11 signaling, leading to phospholipase C activation, IP3 generation, and intracellular calcium release. This calcium signal is critical for GH secretion.

Pituitary GH Release: In somatotroph cells of the anterior pituitary, the calcium signal triggers fusion of GH-containing secretory vesicles with the cell membrane, releasing growth hormone into circulation.

Hypothalamic Effects: GHRP-2 also acts on GHS-R1a expressed in the arcuate nucleus of the hypothalamus, stimulating neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons. This contributes to both GH release (through effects on GHRH neurons) and appetite stimulation.

The net effect is a rapid, dose-dependent increase in circulating growth hormone levels, typically peaking 15-60 minutes after administration.

Physiological Effects Beyond GH Release

While growth hormone stimulation is the primary research focus, GHRP-2 produces several other physiological effects through GHS-R1a activation:

Appetite Stimulation: Like ghrelin, GHRP-2 increases food intake by activating hypothalamic feeding centers. However, the appetite effect is less pronounced than with GHRP-6, making GHRP-2 somewhat more selective for GH release versus feeding.

Cortisol and Prolactin Release: At higher doses, GHRP-2 can stimulate release of other pituitary hormones including ACTH (leading to cortisol secretion) and prolactin. This reflects the broader expression pattern of GHS-R1a and related receptors.

Gastric Motility: Ghrelin receptor activation affects gastrointestinal function, potentially influencing gastric emptying and intestinal motility.

Cardiovascular Effects: GHS-R1a is expressed in cardiac tissue, and ghrelin analogs have been studied for cardioprotective effects, though this is not the primary focus of GHRP-2 research.

The multiplicity of effects distinguishes GHRP-2 from more selective GH secretagogues like ipamorelin, which targets GHS-R1a with minimal effects on other hormone systems.

Clinical Research and Applications

GHRP-2 has been extensively studied in human clinical trials, with particular focus on diagnostic and therapeutic applications:

GH Deficiency Diagnosis: GHRP-2 (as pralmorelin) is approved in Japan as a diagnostic agent for growth hormone deficiency. The peptide stimulates GH release in healthy individuals but shows blunted responses in true GH deficiency, providing a pharmacological test of pituitary function. Multi-center trials established that pralmorelin at 1 mcg/kg IV produces GH response >15 mcg/L in healthy subjects versus <15 mcg/L in severe GHD.

Appetite Research: Studies published in the Journal of Clinical Endocrinology & Metabolism demonstrated that GHRP-2 increases food intake in healthy men, confirming the orexigenic pathway activated by ghrelin receptor agonists. This effect appears independent of GH release, suggesting distinct hypothalamic mechanisms.

Pediatric Growth Disorders: Research has explored GHRP-2 in children with growth hormone deficiency, with studies showing increased appetite and weight gain alongside growth effects.

Body Composition: The anabolic effects of increased GH secretion have been studied for potential applications in muscle wasting, cachexia, and age-related sarcopenia, though these remain investigational.

GHRP-2 vs. Other GH Secretagogues

Understanding GHRP-2’s position requires comparison with related compounds:

GHRP-6 is the first-generation growth hormone releasing peptide. GHRP-2 offers improved potency and reduced appetite stimulation compared to GHRP-6, representing a refinement of the chemical scaffold.

Hexarelin is a more potent GH secretagogue but with greater effects on cardiac tissue and less favorable selectivity profile. GHRP-2 occupies a middle ground in terms of potency and selectivity.

Ipamorelin is a more selective GHS-R1a agonist with minimal effects on cortisol and prolactin. It represents a newer generation of GH secretagogues with improved pharmacological selectivity compared to GHRP-2.

Ibutamoren (MK-677) is an orally active non-peptide ghrelin receptor agonist with longer duration of action. Unlike GHRP-2, it can be administered orally, but with less precise control over GH pulse timing.

GHRH Analogs like sermorelin work through completely different receptors and mechanisms, stimulating GH release through the GHRH receptor rather than GHS-R1a.

Research Applications and Considerations

Laboratories working with GHRP-2 have a well-characterized tool for investigating ghrelin receptor pharmacology and growth hormone physiology. Research applications include:

• GH secretion studies: Characterizing pituitary function and GH pulse dynamics
• Receptor pharmacology: Structure-activity relationships at GHS-R1a
• Appetite regulation: Mechanisms of feeding behavior and energy homeostasis
• Body composition: Effects on lean mass, fat mass, and metabolic parameters
• Aging research: GH axis function in age-related hormonal changes

The peptide is typically administered via subcutaneous injection due to peptide nature limiting oral bioavailability. Standard reconstitution uses bacteriostatic water, with storage of lyophilized powder under refrigeration.

As with all research peptides, GHRP-2 is intended strictly for laboratory investigation and is not approved for human use outside of approved diagnostic applications in Japan.

Current Status and Availability

GHRP-2 (as pralmorelin) holds approved status in Japan as a diagnostic agent for growth hormone deficiency. In other jurisdictions, including the United States and Europe, it remains an investigational compound without regulatory approval for therapeutic use.

The extensive clinical data from Japanese diagnostic use provides valuable safety and efficacy information that supports research applications. The well-established pharmacokinetic and pharmacodynamic profile makes GHRP-2 a useful reference compound for studying GHS-R1a function.

For research laboratories, GHRP-2 offers a balance of potency, selectivity, and characterization that makes it suitable for studies requiring robust GH secretagogue activity with manageable side effect profiles.

Explore our comprehensive selection of research peptides and endocrine compounds for your laboratory studies. Visit our homepage to discover the latest additions to our research catalog.

References

• “Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of Clinical Endocrinology & Metabolism. https://academic.oup.com/jcem/article-abstract/90/2/611/2836522
• “Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” PubMed. https://pubmed.ncbi.nlm.nih.gov/15699539/
• “Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse.” American Journal of Physiology-Endocrinology and Metabolism. https://journals.physiology.org/doi/full/10.1152/ajpendo.00203.2005
• “Pralmorelin.” Wikipedia. https://en.wikipedia.org/wiki/GHRP-2
• “Growth hormone secretagogue.” Wikipedia. https://en.wikipedia.org/wiki/Growth_hormone_secretagogue

Disclaimer: This product is sold for laboratory research purposes only. GHRP-2 is not intended for human consumption, medical treatment, or diagnostic use outside of approved jurisdictions. It is approved as a diagnostic agent in Japan but remains investigational in most other regions. This information is provided for educational purposes and does not constitute medical or scientific advice. Always consult relevant scientific literature and follow proper laboratory safety protocols.